Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. PET/MRI for Preoperative Planning in Patients with Soft Tissue Sarcoma: A Technical Report of Two Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report

    Research output: Contribution to journalJournal articleResearch

  1. Ciclosporin

    Research output: Book/ReportReportCommissioned

  2. Factors associated with citation of original articles in 5 high-impact-factor dermatology journals

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Patients with a familial predisposition to hidradenitis suppurativa have a distinct clinical phenotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis

    Research output: Contribution to journalReviewpeer-review

View graph of relations

Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria. Several randomised controlled trials have investigated the safety, tolerability, and efficacy of omalizumab for chronic urticaria. The safety of omalizumab in pregnancy is not known. We describe a female patient with chronic spontaneous urticaria who was treated with omalizumab continuously through two consecutive pregnancies with convincing results and no apparent toxicity.

Original languageEnglish
JournalCase reports in medicine
Volume2015
Pages (from-to)368053
ISSN1687-9627
DOIs
Publication statusPublished - 2015

ID: 46234646